Concepedia

Andre Overesch

AO

Statistics

Publications

5

Citations

108

H-Index

5

Active since

2020

Affiliations

Affimed Therapeutics (Germany)(Current)

Kettering University

Memorial Sloan Kettering Cancer Center

Sir Charles Gairdner Hospital

Monash Health

Andre Overesch is an author at Affimed Therapeutics (Germany) specializing in cancer immunotherapy, natural killer cell function, and life sciences.

ORCID

Publications per year

2020–2025

5

Publications

5

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

Yago Nieto, Pinaki P. Banerjee, Indreshpal Kaur et al. · Nature Medicine · 2025 · 55 citations · Full text

, , +16

Acute Cystitis Symptom Score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: Clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy

Jakhongir F. Alidjanov, Andre Overesch, Dimitri Abramov-Sommariva et al. · Investigative and Clinical Urology · 2020 · 14 citations · Full text

, , +13

Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)

Won Seog Kim, Jake Shortt, Pier Luigi Zinzani et al. · Cancer Research · 2023 · 14 citations

, , +15

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas

Won Seog Kim, Jake Shortt, Pier Luigi Zinzani et al. · Clinical Cancer Research · 2024 · 14 citations · Full text

, , +14

AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)

Alison J. Moskowitz, A. Harstrick, Michael Emig et al. · Blood · 2023 · 11 citations

, , +16

1–5 of 5